Promise Details
Kennedy announced new FDA-funded trials into folate pathway therapy for autism, focusing on leucovorin as potential adjunct treatment. The initiative was controversial but framed as evidence-driven science rather than ideology. Autism-advocacy groups expressed cautious optimism, noting lack of prior government funding for such trials. Studies are in early recruitment phase.
Current status
As of November 8, 2025: leucovorin clinical trials and autism-pathway research initiatives have begun recruitment, but outcomes and long-term treatment recommendations are pending study completion.
Sources
The information presented in this promise is aggregated from various publicly available sources. We do not claim ownership or guarantee the accuracy of the content. All data is collected and cross-validated from multiple independent sources. To read more about this promise, please view the source links below:
Support Our Work
Help us keep the website running and free for everyone by supporting us:
